Company intelligence / Profile preview

Grit and Polish

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Grit Biotechnology has advanced its lead program GT101—an unmodified TIL therapy—into pivotal Phase II trials for recurrent solid tumors. GT201, a next-generation TIL product with membrane-bound IL‑15 complex, is in Phase I trials after IND clearance in both the US and China. The pipeline also includes preclinical programs such as APC-targeted neoantigen cancer vaccines and nonviral nanoparticle-directed in vivo CAR-T therapies

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyGene therapyTumor-infiltrating lymphocyte (TIL) therapymRNA-based drugsSmall molecule (for gene editing tools)Vaccine
Industry: Biotech

Partnerships

Vitalgen BioPharma Co., Ltd. – collaboration on gene-editing and vaccine delivery technologiesMultiple leading healthcare investors including CICC Capital as financial partners/funders

Beyond the preview

Go deeper on Grit and Polish.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grit and Polish.

Explore the full profile